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SUMMARY
The association between herpes zoster and subsequent cancer risk is still unclear. Consequently,
doubts remain regarding the need for investigation of herpes patients for co-existing or
subsequent malignancy. This is a retrospective cohort study comparing cancer risk in patients
after herpes zoster and age-/sex-matched non-herpes zoster patients, in a primary care-based
continuous morbidity database. We tested for interaction by gender, age, diabetes, HRT use
or antiviral therapy. Analyses were repeated for patients with and without herpes simplex.
The hazard ratio (HR) comparing cancer risk in herpes zoster vs. control patients was significant
in all women, women aged >65 years and subgroups of breast and colorectal cancer (HRs 1·60,
1·82, 2·14, 2·19, respectively). For men, a significant association was found for haematological
cancers (HR 2·92). No associations were found with herpes simplex. No interaction was
identified with antiviral therapy, diabetes or HRT treatment. We concluded that there was
a moderate significant association between herpes zoster and subsequent cancer risk in women
aged >65 years, without any influence of antiviral therapy. No association was found with
herpes simplex. There is insufficient reason for extensively testing older patients with herpes
zoster or herpes simplex for the presence of occult cancer.
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INTRODUCTION
Herpes zoster usually emerges as anti-varicella zoster
virus antibodies and T cell responses wane with age
[1]. Given that the incidence of most malignancies is
also strongly related to ageing, there have been several
attempts to try to determine whether the emergence
of zoster could be used as a marker of increased risk
of cancer and a signal to actively seek occult malig-
nancy. Studies so far have been contradictory [2–7].
Using data of 311000 patient-years, we previously
demonstrated an increased risk of malignancy in
women aged >65 years [3], suggesting that herpes zos-
ter infection may be a marker of a cancer-susceptible
immune system.
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It has been difficult to provide a definitive answer
regarding the association of zoster with malignancy
in community settings, due to the limited size of avail-
able datasets. Using our general practice (GP)-based
morbidity register we analysed data relating to 1474993
patient-years. We used this dataset to re-examine
cancer risk in patients with and without previous
herpes zoster, controlling for age and gender. We
also tested whether any association with malignancy
is specific for herpes zoster or also present for other
herpes virus infections. If such relation is present,
this can refer to either a direct association between
herpes and malignancy or to the effect of treatment
given. We therefore tested whether there would be
any effect modification by antiviral therapy.
PATIENTS AND METHODS
Patients
Data were obtained from Intego, an ongoing general
practice-based morbidity registration network based
in the Department of General Practice at the
Catholic University of Leuven [3]. Ninety GPs evenly
spread over Flanders, Belgium collaborated in the
Intego project. Before their data are included, their
registration performance is audited and only data
from the practices with the best recording performance
(less than 50% of the applicants) are included in the
database. The Intego GPs are continuously and pro-
spectively registering all new diagnoses together with
new drug prescriptions, laboratory test results, and
some background information (including gender and
year of birth), using keywords linked to codes. Using
specially framed extraction software, new data are
collected from the GPs’ computers and entered into
a central database. Registered data are continuously
updated and historically accumulated for each patient.
New diagnoses are classified according to ICPC-2
(International Classification of Primary Care) [8],
a classification system for morbidity in GP accepted
and used worldwide. Medications are classified accord-
ing to the WHO’s Anatomical Therapeutic Chemical
(ATC) classification system [9]. The Intego population
represents the Flemish population with respect to age
and gender distribution [10].
For this study, diagnoses and prescribed medi-
cations recorded during the years 1994–2008 were
used, together with their dates. They cover infor-
mation on 215251 different patients and 1474993
patient-years. This includes almost 2% of the Flem-
ish population.
Definitions and codes
Within the Intego network, no predefined criteria
were used for entering a diagnosis. The registering
GPs used their own clinical skills and used additional
tests as considered appropriate. In complex medical
conditions, or in case of a patient directly consulting
a specialist, inclusion is based on specialist diagnoses
that are reported to the GP by letter. This infor-
mation is considered to be complete, with some
uncertainties in ophthalmology, gynaecology and
paediatrics.
Since herpes zoster is a clinical diagnosis, no other
methods of confirmation of this diagnosis were used.
Our incidence rate (3·3/1000 person-years) was con-
sistent with other studies (between 3·2 and 4·2 cases/
1000 person-years) [11]. We separately tested for a
possible inclusion of prevalent cases by comparing
the incidence in the first registration year with sub-
sequent years and found no differences [12]. The
same reasoning applied for herpes simplex. For herpes
simplex, diagnoses of herpes labialis (type 1) and
herpes simplex (type 2) were combined.
A different method was used to ascertain incident
cases of malignancy. We selected a random sample
of patients with a diagnosis of malignancy per practice
and asked the physicians for the tests on which each
diagnosis was based. We received information from
48 practices and 463 patients. Two patients could
not be retrieved by the GP, the diagnosis was
confirmed histologically in 73%, at least cytologically
in an additional 8%, and based on magnetic resonance
imaging (MRI), computerized axial tomography
(CAT) scan or endoscopy in 10%. Four percent was
based on classical radiology and 2% were clinical
diagnoses. Of the 14 remaining cases no information
on method of diagnosis was available, but 12 of
the cases were diagnosed during a hospital stay.
The Intego cancer incidence (3·63/1000 patient-years)
was largely similar to a local cancer registry [13]
(4·25/1000 person-years over 1996–2005). In accord-
ance with the rules in most cancer registries, basal
cell carcinoma was not considered as a malignancy.
Antiviral drug was defined as a drug classified
under ATC code J05AB [9].
Retrospective cohort study
Patients with a diagnosis of herpes zoster between
1 January 1994 and 31 December 2008 were included,
with the date of diagnosis as the baseline date.
Controls without any diagnosis of herpes zoster were
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randomly matched to the cases by year of birth and
gender. We aimed to match six controls to each
case, although for some cases only four or five con-
trols were available. The date of diagnosis of the
index patient was assigned to the no-herpes zoster
patients as the baseline date for the study. To prevent
double use of control patients when more than one
patient from the same sex and year of birth was diag-
nosed with the index disease, such dates were ran-
domly assigned to all control patients from the same
sex and birth year. Similar matching was done for
all cases of herpes simplex.
In both groups, we excluded those who were di-
agnosed with malignancy before or at the date of
inclusion. Both groups of patients (with and without
the index disease) were followed for an emerging
first diagnosis of malignancy. Follow-up of patients
lasted until the end of the registration period, or
earlier in case of emergence of cancer or a patient
leaving the Intego patient population, e.g. by reloca-
tion or death.
Analysis
All analyses were performed separately for men and
women.
Survival analyses were performed to take account
of the censored nature of the data, For patients with-
out any diagnosis of cancer, due to privacy regu-
lations, only the last year of contact could be
obtained, not the exact date. Hence, for those patients,
the last date of contact was set to 30 June of that year.
Kaplan–Meier curves were calculated for time to
diagnosis of cancer for patients with and without
herpes zoster/herpes simplex. In order to take account
of the matched nature of the data, a weighted Kaplan–
Meier curve for matched data was constructed [14].
In addition, a Cox regression was performed
whereby the matched nature of the data was ac-
counted for by using the robust sandwich estimate
of Lin & Wei [15] for the covariance matrix. All ana-
lyses were also performed for each gender separately,
and adjusted for age. Hazard ratios (HR) and their
95% confidence intervals (CI) were calculated and
differences tested by means of a Wald test, using the
robust sandwich estimator for the standard error
[13]. The proportional hazards assumption was
assessed by visual inspection of the Kaplan–Meier
curves and was found to be satisfied. We additionally
performed further checks of the appropriateness of the
proportional hazards assumptions using the methods
described by Lin et al. [16] using cumulative sums of
martingale residuals. Although small deviations were
found for some of our analyses, generally the assump-
tion was sufficiently satisfied.
Subgroup analyses were defined a priori and per-
formed for age groups, antiviral drug use after
the herpes diagnosis, hormone replacement therapy
(HRT) use (in women only), and comorbid diabetes
at baseline. Due to the expected low number of
cases of malignancies and herpes zoster cases aged
465 years, the latter analyses were restricted to
patients aged >65 only. Cancer-specific incidence of
cancer according to herpes zoster was estimated using
cumulative incidence functions (Figs 3, 4).
We formally tested for interaction between herpes
zoster and antiviral treatment, HRT use and diabetes.
Statistical tests were two-sided and performed at a sig-
nificance level of 5%. Due to the exploratory nature
of the study, no adjustments were made to the sig-
nificance levels to account for multiple testing [17].
All analyses were performed using SAS software,
version 9.2 [18].
Ethical considerations
Before sending the data to the central database,
patient identification information was encrypted in
each practice using a one-way encryption algorithm.
As a result, only the registering GP is able to identify
which patient a certain code belongs to. Because of
the large number of patients involved, it is impossible
to individually inform each patient concerned. How-
ever, according to the national privacy law patients
are informed about the registration through posters
displayed in the waiting rooms of the GPs. The
Intego procedures have been approved by the ethical
review board of the Medical School of the Catholic
University of Leuven (no. ML1723).
RESULTS
Patient characteristics
In total, 2635 women and 2186 men had a diagnosis
of herpes zoster, and were matched with 12827 and
10594 controls, respectively. Following a diagnosis
of herpes zoster, 75 (2·8%) women and 78 (3·6%) men
had a diagnosis of cancer compared to 159 (1·2%)
female and 216 (2·0%) male controls (Table 1).
Median time from herpes zoster to cancer diagnosis
was 3·00 years (range 1·34–6·02 years).
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A total of 1561 women and 932 men had a first
diagnosis of herpes simplex, to which 7686 female
and 4599 male controls were matched, respectively.
Following a diagnosis of herpes simplex, 20 (1·3%)
women and 14 (1·5%) men had a diagnosis of cancer
compared to 68 (0·9%) female and 56 (1·2%) male
controls (Table 1). The median time from herpes
simplex to cancer diagnosis was 4·09 years (range
1·77–8·63 years).
The number of patients with herpes zoster treated
with antiviral drugs was 1239 (57%) and 1534 (58%)
in men and women, respectively. For patients with
herpes simplex the numbers were 218 (23%) and
416 (27%).
Demographic characteristics of all patients are
listed in Table 2.
Herpes zoster and subsequent cancer risk
Crude data analysis
The overall HR for both men and women together,
adjusted for age (spline) and gender was 1·37 (95%
CI 1·14–1·66, P=0·001), indicating a significantly
higher risk of subsequent malignancy after herpes zos-
ter compared to controls. There was no interaction
between herpes zoster and gender (P=0·12).
HRs by gender and age group are summarized
in Table 3. The estimated HR for the comparison
between cases and controls in women was 1·60 (95%
CI 1·21–2·11, P< 0·001). The Kaplan–Meier curve
is presented in Figure 1. The HR after 1 year of
follow-up was 2·11 (95% CI 1·15–3·87).
The estimated HR for the comparison between cases
and controls in men was 1·09 (95% CI 0·91–1·54,
Table 1. Flowchart of the study population
Intego population total (N=215251)
Men (n=104894) Women (n=110357)
Herpes zoster
(herpes simplex)
Yes No Yes No
All patients 2186 (932) 102708(103962) 2635 (1561) 107722(108796)
Included in the study* 2186 (932) 10594(4599) 2635 (1561) 12827(7686)
Subsequent malignancy Yes No Yes No Yes No Yes No
78 (14) 2108 (918) 216 (56) 10378 (4 543) 75 (20) 2560 (1 541) 159 (68) 12668 (7 618)
* All herpes zoster (herpes simplex) patients and a random sample of matched controls.
Table 2. Descriptive characteristics of the study population
Patients
with
herpes
zoster
(n=4821)
Patients
without
herpes
zoster
(n=23421)
Patients
with
herpes
simplex
(n=2493)
Patients
without
herpes
simplex
(n=12285)
Number of patients with
malignancy (%)
153 (3·2) 375 (1·6) 34 (1·4) 124 (1·0)
Mean age at baseline,
years (S.D.)
47·5 (23) 46·8 (23) 35·9 (21) 35·6 (20)
Sex, n (%)
Men 2186 (45) 10594 (45) 932 (37) 4599 (37)
Women 2635 (55) 12827 (55) 1561 (63) 7686 (63)
Age group at baseline, years (%)
0–50 2248 (47) 11176 (48) 1872 (75) 9299 (76)
51–65 1172 (24) 5697 (24) 382 (15) 1858 (15)
>65 1401 (29) 6548 (28) 239 (10) 1128 (9)
S.D., Standard deviation.
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P=0·20), thus yielding no statistical evidence of an
association between herpes zoster and subsequent
malignancy in men.
Subgroup analyses according to age and cancer
localization
Subgroup analyses in women revealed that the associ-
ation between herpes zoster and a subsequent cancer
diagnosis was only relevant in the older age groups,
especially for breast and colorectal cancer. For indi-
viduals aged >65 years, the HR for any cancer was
1·82 (95% CI 1·25–2·66, P=0·002) (Fig. 2). A statisti-
cally significant association was also found between
herpes zoster and diagnosis of colorectal cancer
(HR 2·19, 95% CI 1·00–4·80, P=0·05) and breast cancer
(HR 2·14, 95% CI 1·11–4·12, P=0·02). No evidence
for an association between herpes zoster and lung
or haematological cancer could be found (Table 3).
Cancer-specific cumulative incidence functions are
presented in Figures 3 and 4.
For men, subgroup analyses for age and cancer
localization showed a statistically significant associ-
ation for haematological cancer (HR 2·92, 95%
CI 1·20–7·08, P=0·02) only (Table 3).
In patients aged >50 years, the significant associ-
ations were exactly the same, albeit with slightly
lower HRs (data not shown).
Table 3. Association between herpes zoster and subsequent malignancy: estimated age-adjusted hazard ratios
according to age group, site and gender
Age (no. of events in men+women) Site Men HR (95% CI) Women HR (95% CI)
All (294+234) All 1·09 (0·91–1·54) 1·60 (1·21–2·11)
450 (9+38) All 0·87 (0·20–3·72) 1·16 (0·56–2·41)
51–65 (90+75) All 1·07 (0·67–1·73) 1·53 (0·93–2·50)
>65 (195+121) All 1·28 (0·93–1·75) 1·82 (1·25–2·66)
>65 (50+5) Lung 1·19 (0·63–2·25) 0·92 (0·11–7·94)
>65 (53+0) Prostate 1·10 0·59–2·05) †
>65 (0+37) Breast † 2·14 (1·11–4·12)
>65 (23+26) Colorectal 1·84 (0·78–4·34) 2·19 (1·00–4·80)
>65 (19+14) Haematological 2·92 (1·20–7·08) 0·58 (0·13–2·62)
HR, Hazard ratio; CI, confidence interval.
†No cases of malignancy were recorded.
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Fig. 1. Time to emergence of malignancy after herpes zoster or matching date in all women.
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The effect of possible effect modifiers
Formal analyses in patients aged >65 years showed
no statistical interaction between antiviral drug use,
diabetes or HRT use and herpes zoster.
Herpes simplex and subsequent cancer risk
Crude data analysis
The HR for the comparison between women or men
with and without herpes simplex was 1·06 (95% CI
0·64–1·74) or 0·91 (95% CI 0·49–1·70), suggesting
absence of association (Table 4). A Kaplan–Meier
curve is presented in Figure 5.
Subgroup analyses according to age and cancer
localization
Subgroup analyses revealed no significant associations
for any of the subgroups. Care should be taken with
the analyses by cancer type due to the low number
of events for patients with herpes simplex (Table 4).
DISCUSSION
Summary of main findings and relationship with the
existing literature:
Our results indicate a moderate association between
herpes zoster and subsequent cancer risk in women
aged >65 years. In this group, 102 (95% CI 51–333)
cases of herpes zoster are related to one additional
malignancy. The association was largely similar
during the first year, with one additional malignancy
for 282 cases of herpes zoster. This association was
most prominent for breast and colorectal cancer. In
men a significant association was absent for all ma-
lignancies except haematological cancers. No associ-
ations could be found in men or women between
herpes simplex and cancer. These results confirm
and enlarge the initial results reported in our previous
study based on the first 7 years of registration [3].
Our results are largely comparable to the results of
a recently published, similar, larger and UK-based
study [6], although in that study the results for men
only were also significant. Another recent study from
Taiwan [7] resulted in significantly positive HRs for
men and women combined for the first 2 years only.
No gender-stratified results were reported. No relation-
ship could be identified in patients aged 450 years.
However, such a relationship would be difficult to
prove, due to the low number of patients with herpes
zoster and cancer in these age groups, even in a
large cohort. As a sensitivity analysis, we also tested
the associations in the population aged >50 years.
The results were largely similar as for patients aged
>65 years, although with slightly lower HRs.
The restriction of significant results for women only
is less easy to explain. However, the 95% CIs of HRs
for men and women overlap, so a power problem may
be involved.
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Fig. 2. Time to emergence of malignancy after herpes zoster or matching date in women aged >65 years.
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The association with haematological cancer in
males could result from HIV. However, the number
of patients with HIV infection in the whole database
is only 13. An intermediate effect of sex hormones
could be hypothesized, at least for breast cancer; the
influence of HRT in the emergence of breast cancer
has extensively been described [19, 20]. In a post-hoc
sensitivity analysis, we compared the association
between herpes zoster and subsequent breast cancer
risk in patients with and without HRT use and
found similar HRs (2·27 and 2·19).
As the association between herpes zoster and sub-
sequent cancer diagnosis was not larger during the
first year of follow-up, the results do not support an
important role of acute herpes zoster as a marker
of an undiagnosed malignancy as regularly discussed
since 1955 [3, 5–7, 21, 22].
Possible mechanisms
We tested for possible effect modification by antiviral
treatment and diabetes on the association between
herpes zoster and subsequent cancer risk and found
none. This finding on antiviral treatment is also con-
gruent with previous studies indicating absence of a
carcinogenic effect of antivirals [23].
As some cancers are known to be present in a pre-
clinical and undetectable form for 510 years before
diagnosis [24, 25], herpes zoster could be an early
manifestation of the impairment of the immune sys-
tem provoked by the (occult) malignancy. It seems
impossible, however, to test this hypothesis.
Alternatively, it is possible that herpes zoster virus
provokes antigenic stimulation or changes tissue anti-
gen with some effect on the development of malig-
nancy. Such reasoning is supported by the finding of
different types of malignancies (lymphoma, pseudo-
lymphoma, angiosarcoma, Kaposi’s sarcoma) at the
same site as a previous herpes zoster infection [26, 27].
Finally, both reactivation of the virus and immuno-
logical surveillance against malignancy [28, 29] are
related to cellular immunity (CD4+ and CD8+ T cells
and natural killer cells). Any dysfunction of such
a mechanism can therefore result in the emergence
of both herpes zoster and malignancy. In some cases
herpes zoster would emerge first and in other cases
malignancy.
Finally, possible confounders we do not know or
expect, and therefore cannot control, or even an indi-
cator effect of herpes zoster for another exposure
factor unknown to us could influence our results.
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Fig. 3. Time to emergence of breast cancer after herpes zoster
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The fact that no association was found between
a clinical episode of herpes simplex and subsequent
cancer risk suggests a virus-specific effect of herpes
zoster and not herpes simplex, probably interacting
with a more serious degree of immunosenescence.
Herpes simplex virus 1 and 2 and the varicella virus
are all alpha-herpes viruses, but genetically they are
very different. However, failure to find an association
may result from either absence of such an association
or low power. Contrary to herpes zoster, herpes sim-
plex will not always trigger a contact with a physician.
An unknown proportion of patients will accept this
condition as something that will come and go without
any need to seek professional medical care. For our
analysis, this would result in a bias towards a null
effect. Even if an underlying immunological mechan-
ism were present, it would be difficult to detect and
relate to subsequent cancer occurrence.
Weaknesses
It should be borne in mind that the censoring in this
database is not necessarily non-informative: diagnosing
one disease (e.g. herpes zoster) could easily stimulate
increased searching and diagnosing of other diseases
(e.g. malignancy). Additionally, healthcare-seeking
Table 4. Association between herpes simplex and subsequent malignancy: estimated age-adjusted hazard ratios
according to age group, site and gender
Age (no. of events in men+women) Site Men HR (95% CI) Women HR (95% CI)
All (70+88) All 0·91 (0·49–1·70) 1·06 (0·64–1·74)
450 (5+32) All 0·80 (0·08–8·08) 1·17 (0·52–2·63)
51–65 (30+28) All 1·01 (0·41–2·46) 0·85 (0·33–2·18)
>65 (35+28) All 0·68 (0·35–2·11) 1·18 (0·49–2·87)
>65 (11+0) Lung 0·84 (0·18–3·97) †
>65 (9+0) Prostate ‡ †
>65 (0+8) Breast † 1·18 (0·24–5·82)
>65 (1+7) Colorectal † 1·42 (0·24–8·54)
>65 (6+7) Haematological 2·06 (0·37–11·56) 1·48 (0·29–7·44)
HR, Hazard ratio; CI, confidence interval.
†No cases of malignancy were recorded in at least one of the comparison groups.
‡Only one case of malignancy was recorded in at least one of the comparison groups.
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Fig. 5. Time to emergence of malignancy after herpes simplex or matching date in all female patients.
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behaviour of patients seen after herpes zoster may be
different from individuals without herpes. Therefore,
a diagnosis of malignancy could be made earlier in
herpes patients and inflate the HR. However, the pres-
ence of such indication bias would result in a biased
association during the first months after the first dia-
gnosis only. In our study, although there was an associ-
ationbetweenherpes zosterand subsequentmalignancy
during the first year in women aged >65 years, the HR
of 2·11 for the first year was even lower than the HR in
following years.
The percentages of non-cancer patients censored
during follow-up and before study end were 54% for
patients without and 32% for patients after herpes
zoster. In patients without malignancy, the mean
follow-up time was also shorter in the group without
herpes zoster compared to the zoster group. It is poss-
ible that patients die faster in the non-zoster group and
therefore have less time available to develop a malig-
nancy, but the opposite is also possible: these patients
may be very healthy and not have visited a physician
for many years. Because date of death is not available,
we cannot test these hypotheses.
In a study testing for a large number of possible
associations, we also have to deal with a multi-
comparison problem. As this is an observational
study and in accordance with Rothman [17] and
many others, we decided not to formally adjust our
P values by using a Bonferroni or other method.
However, for all cancers and for breast cancer in
women aged >65 years, we found P values of 0·001
and 0·002, respectively. Moreover, for all significant
associations in patients aged >65 years the measures
of effect (HRs) were very reassuring.
The mean age of herpes zoster patients tends to be
older compared to herpes simplex patients. As a result
of the matching of controls by age this is also the case
for their respective control groups. As age is the main
risk factor for malignancy, it is normal that cancer
incidence is higher in the zoster control group than
in the simplex control group.
Diagnosis of herpes is a clinical diagnosis and there-
fore susceptible to measurement bias. It is encoura-
ging, however, that our rates of herpes zoster are
comparable to those reported in the literature.
Strengths
Our results are based on routinely collected data with-
out any selection apart from the decision of a patient
to present his complaints to a physician or not, and
thus originate from real life. The analyses include
the major cancer locations with sufficient power and
we were able to test for effect modification by relevant
comorbidities or drug treatment. Follow-up ranges up
to a maximum of 15 years.
Implications for future research
The presence of additional comorbid diseases or
chronic use of medication at baseline, or even the sever-
ity of herpes zoster or the frequency of contact with
children (and therefore the likelihood of re-exposure
to the virus) might influence the associations we
described. We have no realistic hypothesis, however,
about the nature or mechanisms of such an effect.
Testing a large number of comorbid diseases for a poss-
ible confounding effect would be possible, even within
the framework of the Intego database. It would, how-
ever, enormously increase the multi-comparison pro-
blem, decrease statistical power and easily degenerate
into a fishing expedition. Additionally this report
may stimulate researchers from other disciplines to
start research into the immunological basis of our
findings.
Implications for clinical practice
As a general conclusion, at present we see no reason
for extensively testing for occult cancer in patients
with a clinical episode of herpes zoster or herpes sim-
plex. However, our results highlight the need for clin-
icians to carefully follow the current cancer screening
and early diagnosis guidelines in women after herpes
zoster.
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